MannKind Finally Finds a Partner for its Inhaled Insulin Afrezza® in Sanofi
By Heather Cartwright
Pharma Deals Review: Vol 2014 Issue 9 (Table of Contents)
Published: 24 Sep-2014
DOI: 10.3833/pdr.v2014.i9.2062 ISSN: 1756-7874
Section: Distribution & Marketing
Fulltext:
Abstract
Sanofi has licensed global rights to MannKind’s rapid-acting inhaled insulin Afrezza® (insulin human), which was approved by the US FDA in June 2014 for the treatment of diabetes mellitus at the third attempt...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS